The update will be presented by the Company's Chief Scientific Officer, Professor Magnus Essand, during an invited scientific presentation at the 10th Zurich Immuno-Oncology Conference 2026 in Zürich, Switzerland. The conference, held at Universitätsspital Zürich, brings together leading researchers and clinicians to discuss innovations in immuno-oncology.

The presentation will include new data from two patients enrolled in cohort 3 (the highest dose level to date) of the CARMA study, as well as longer-term follow-up data from patients treated in the previous two cohorts (dose levels 1 and 2).

The CARMA study is evaluating the safety and preliminary efficacy of ELC-301, an autologous CD20-directed CAR T-cell therapy armed with the company's iTANK-technology, in patients with relapsed or refractory B-cell lymphoma.

Previous updates from the first two cohorts (presented e.g. at the Karolinska ATMP Center inauguration in August 2025) showed promising signals, including complete metabolic responses in four of six treated patients, a favorable safety profile, and no dose-limiting toxicities observed to date.

"We are pleased to share the next data update from the CARMA study in this prestigious scientific forum," said Professor Magnus Essand, Chief Scientific Officer of Elicera Therapeutics. "The presentation will highlight our efforts to optimize CAR T-cell performance through the iTANK platform, aiming for enhanced anti-tumor activity while minimizing toxicity - key challenges in solid and hematological malignancies."

The company expects to issue a separate press release with key highlights from the presentation in connection with the event on March 6, 2026.

For more information: https://www.usz.ch/en/event/10th-zurich-immuno-oncology-conference-2026/